At the news
? NEUTRALIMPACT 4/10 8-K filed Jun 10, 2026 at 06:01 ET
InMed Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement, closing a delisting notice received on March 27, 2026. The company demonstrated a closing bid price at or above $1.00 for 10 consecutive business days through June 2, 2026. This is a procedural compliance update, it removes an immediate delisting overhang but does not change the company's operational or financial trajectory.
- InMed received a Nasdaq deficiency notice on March 27, 2026 for non-compliance with the $1.00 bid price rule (Rule 5550(a)(2))
- Nasdaq confirmed compliance on June 3, 2026, based on 10 consecutive business days (May 19–June 2, 2026) with closing bid at or above $1.00
- The matter is now closed with no further action required by Nasdaq
- Company has a market cap of ~$4M and analyst consensus is 0% bullish (3 Hold, 4 Sell, 1 Strong Sell)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access